Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK Study of HEC68498 in Healthy Subjects
NCT03502902Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing HEC68498 with Placebo (2 arms). Primary endpoint: Adverse event up to 4 weeks. Started Apr 2018; status: completed.
02
Drugs
HEC68498
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03502902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502902.